Characteristics of t(8;21) AML
| Characteristic . | Risk directed . | Not risk directed . | |||||
|---|---|---|---|---|---|---|---|
| Low risk—chemo (n = 29) . | High risk—HSCT (n = 40) . | Total . | Low risk—HSCT (n = 18) . | High risk—Chemo (n = 29) . | Total . | P . | |
| Age (years) | 28 (15-56) | 37 (15-54) | 33 (15-56) | 35 (16-54) | 37 (15-60) | 36 (15-60) | NS |
| Gender (male/female) | 16/16 | 26/14 | 39/30 | 12/6 | 16/13 | 28/19 | NS |
| WBC (109/L) | 5.4 (1.4-79) | 9.0 (1.9-59) | 8.1 (1.4-79) | 6.0 (1.2-30) | 8.0 (2.5-80.5) | 7.2 (1.2-80.5) | NS |
| HGB (g/L) | 83 (34-136) | 81 (49-133) | 81(45-136) | 95 (41-123) | 74 (34-135) | 78 (34-135) | NS |
| PLT (109/L) | 37 (5-286) | 27 (4-108) | 32.5 (4-286) | 33 (2-106) | 35 (7-225) | 34 (2-225) | NS |
| Blasts in BM (%) | 52 (26-89) | 51 (20-86) | 52(20-89) | 56 (21-82) | 39 (24-92) | 46 (21-92) | NS |
| RUNX1-RUNX1T1 (%) | 506 (353-993) | 411(97-1082) | 439 (35-1082) | 422 (98-848) | 358(52-1163) | 380 (43-1163) | NS |
| KIT mutation (%) | 17.6(3/17) | 54.8(17/31) | 54.8(20/48) | 50(5/10) | 34.6(9/26) | 38.9(14/36) | NS |
| Comorbidity score (0/1-2/3)* | 23/17/0 | 18/11/0 | 41/28/0 | 16/13/0 | 11/7/0 | 27/20/0 | NS |
| Characteristic . | Risk directed . | Not risk directed . | |||||
|---|---|---|---|---|---|---|---|
| Low risk—chemo (n = 29) . | High risk—HSCT (n = 40) . | Total . | Low risk—HSCT (n = 18) . | High risk—Chemo (n = 29) . | Total . | P . | |
| Age (years) | 28 (15-56) | 37 (15-54) | 33 (15-56) | 35 (16-54) | 37 (15-60) | 36 (15-60) | NS |
| Gender (male/female) | 16/16 | 26/14 | 39/30 | 12/6 | 16/13 | 28/19 | NS |
| WBC (109/L) | 5.4 (1.4-79) | 9.0 (1.9-59) | 8.1 (1.4-79) | 6.0 (1.2-30) | 8.0 (2.5-80.5) | 7.2 (1.2-80.5) | NS |
| HGB (g/L) | 83 (34-136) | 81 (49-133) | 81(45-136) | 95 (41-123) | 74 (34-135) | 78 (34-135) | NS |
| PLT (109/L) | 37 (5-286) | 27 (4-108) | 32.5 (4-286) | 33 (2-106) | 35 (7-225) | 34 (2-225) | NS |
| Blasts in BM (%) | 52 (26-89) | 51 (20-86) | 52(20-89) | 56 (21-82) | 39 (24-92) | 46 (21-92) | NS |
| RUNX1-RUNX1T1 (%) | 506 (353-993) | 411(97-1082) | 439 (35-1082) | 422 (98-848) | 358(52-1163) | 380 (43-1163) | NS |
| KIT mutation (%) | 17.6(3/17) | 54.8(17/31) | 54.8(20/48) | 50(5/10) | 34.6(9/26) | 38.9(14/36) | NS |
| Comorbidity score (0/1-2/3)* | 23/17/0 | 18/11/0 | 41/28/0 | 16/13/0 | 11/7/0 | 27/20/0 | NS |
There are no differences in the characteristics between the low risk—chemotherapy group and the low risk—HSCT group and between the high risk—chemotherapy group and the high risk—HSCT group. HGB, hemoglobin; PLT, platelet; BM, bone marrow; NS, not significant.
According to the Charlson Comorbidity Index.